Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C
Top Cited Papers
Open Access
- 1 August 2005
- journal article
- Published by Elsevier in Gastroenterology
- Vol. 129 (2), 522-527
- https://doi.org/10.1053/j.gastro.2005.05.008
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3*1, *2Journal of Hepatology, 2004
- Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis CAnnals of Internal Medicine, 2004
- Hepatocellular carcinoma and hepatitis C in the United StatesHepatology, 2002
- Natural history of chronic hepatitis CHepatology, 2002
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus InfectionNew England Journal of Medicine, 2002
- Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialThe Lancet, 2001
- Hepatitis C Virus InfectionNew England Journal of Medicine, 2001
- Prognosis of Chronic Hepatitis C: Results of A Large, Prospective Cohort StudyHepatology, 1998
- Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis CNew England Journal of Medicine, 1998
- Histological grading and staging of chronic hepatitisJournal of Hepatology, 1995